454 related articles for article (PubMed ID: 20138542)
1. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer.
Knudsen KE; Penning TM
Trends Endocrinol Metab; 2010 May; 21(5):315-24. PubMed ID: 20138542
[TBL] [Abstract][Full Text] [Related]
2. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
Mellado B; Marin Aguilera M; Pereira MV
Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
[TBL] [Abstract][Full Text] [Related]
3. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis and progression of prostate cancer.
Schrecengost R; Knudsen KE
Semin Oncol; 2013 Jun; 40(3):244-58. PubMed ID: 23806491
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
Taplin ME; Balk SP
J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
[TBL] [Abstract][Full Text] [Related]
7. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in understanding hormonal therapy resistant prostate cancer.
Donkena KV; Yuan H; Young CY
Curr Cancer Drug Targets; 2010 Jun; 10(4):402-10. PubMed ID: 20464780
[TBL] [Abstract][Full Text] [Related]
10. Hormone treatment for prostate cancer: current issues and future directions.
Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
[TBL] [Abstract][Full Text] [Related]
11. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.
Dehm SM; Tindall DJ
J Biol Chem; 2006 Sep; 281(38):27882-93. PubMed ID: 16870607
[TBL] [Abstract][Full Text] [Related]
12. Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan K; Challa S; Coppola D; Lawrence H; Luo Y; Gevariya H; Zhu W; Chen YA; Lawrence NJ; Mahajan NP
Prostate; 2010 Sep; 70(12):1274-85. PubMed ID: 20623637
[TBL] [Abstract][Full Text] [Related]
13. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.
Sharifi N
Anticancer Agents Med Chem; 2009 Dec; 9(10):1046-51. PubMed ID: 19719456
[TBL] [Abstract][Full Text] [Related]
14. The androgen receptor in hormone-refractory prostate cancer.
Mao HL; Zhu ZQ; Chen CD
Asian J Androl; 2009 Jan; 11(1):69-73. PubMed ID: 19050686
[TBL] [Abstract][Full Text] [Related]
15. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer.
Scher HI; Buchanan G; Gerald W; Butler LM; Tilley WD
Endocr Relat Cancer; 2004 Sep; 11(3):459-76. PubMed ID: 15369448
[TBL] [Abstract][Full Text] [Related]
16. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
17. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor footprint on the way to prostate cancer progression.
Hodgson MC; Bowden WA; Agoulnik IU
World J Urol; 2012 Jun; 30(3):279-85. PubMed ID: 21927983
[TBL] [Abstract][Full Text] [Related]
19. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.
Kageyama Y; Hyochi N; Kihara K; Sugiyama H
Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):203-11. PubMed ID: 18221063
[TBL] [Abstract][Full Text] [Related]
20. Targeting the androgen receptor.
Friedlander TW; Ryan CJ
Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
